Results of a double-blind, randomized study to evaluate the efficacy and safety of antibiophilus® in patients with radiation-induced diarrhoea

European Journal of Gastroenterology and Hepatology

Volumn 13, Issue 4, 2001, Pages 391-396

  Urbancsek, Hilda ^a   Kazar, Tibor ^b   Mezes, Istuan ^b   Neumann, Kurt ^c  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b EIS Executive Information Service Ltd   (Hungary)

^c Kurt Neumann + Team   (Austria)

Author keywords

Diarrhoea; Lactobacillus treatment; Radiation induced

Indexed keywords

ANTIBIO FORTE; ANTIBIOPHILUS; BACILOR; BIOLACTUS; BIOPHILUS; LACTOBACIL; LIOLACTIL; PLACEBO; PROBIOTIC AGENT; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EDEMA; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; LACTOBACILLUS RHAMNOSUS; MAJOR CLINICAL STUDY; MALE; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION ENTEROPATHY; RANDOMIZED CONTROLLED TRIAL; UTERUS CANCER;

ABDOMINAL NEOPLASMS; ADULT; AGED; ANTIDIARRHEALS; DIARRHEA; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LACTOBACILLUS CASEI; MALE; MIDDLE AGED; PROBIOTICS; RADIATION INJURIES; RADIOTHERAPY;

EID: 0035050218     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/00042737-200104000-00015     Document Type: Article

References (24)

1. Elmer GW, Surawicz CM, McFarland LV. Biotherapeutic agents: a neglected modality for the treatment and prevention of selected intestinal and vaginal infections. JAMA 1996; 275: 870-876.
2. Perdigon G, Aguero G, Alvarez S, De Allori CG, Pesce De Ruiz Holgado AA. Effect of viable Lactobacillus casei feeding on the immunity of the mucosae and intestinal microflora in malnourished mice. Milchwissenschaft 1995; 50: 251-256.
3. Tafani JP. Scientific evidence supporting animal performance improvement due to the use of lactic acid bacteria (L.A.B.) in animal feed. Microbiol Aliment Nutr 1984; 2: 407-419.
4. Kato I, Yokokura T, Mutai M. Macrophage activation by Lactobacillus casei in mice. Microbiol Immunol 1983; 27: 611-618.
5. Gruet A, Blonde P. Implantation des ferments lactiques dans l’intestin de souris axéniques. Ann Pharm Fr 1973; 31: 137-142.
6. Laboratoires Lyocentre, Aurillac, France, data on file.
7. Gorbach SL. Lactic acid bacteria and human health. Ann Med 1990; 22: 37-41.
8. Alm L. Effect of fermentation on lactose, glucose and galactose content in milk and suitability of fermented milk products for lactose intolerant individuals. J Dairy Sci 1982; 65: 346-352.
9. Berkow R, Beers MH, Fletcher AJ (editors). The Merck Manual of Medical Information. Merck Research Laboratories; 1997. p. 533.
10. Lichtenstein AH. Intestinal cholesterol metabolism. Ann Med 1990; 22: 49-52.
11. Gurr MI. Effects of fermented milk on cholesterolemia. A critical review of the literature. In:Fermented Milks and Health. Proceedings of a Workshop held on 25-26 September at Arnheem, Netherlands. Ede, The Netherlands: Nizo; 1989. pp. 76-87.
12. Bogdanov IG. Antitumor action of glycopeptide from the cell wall of Lactobacillus bulgaricus. Bull Exp Biol Med 1978; 84: 1750-1753.
13. Moore WEC, Holdeman LV. Some newer concepts of the human intestinal flora. Am J Med Tech 1975; 40: 288-295.
14. De Somine C. Yogurt and the immune response. In:Les Laits Fermentés. Actualités de la Recherche. Congrès International, Paris, 14-16 Decembre 1989. John Libbey Eurotext; 1990. pp. 63-67.
15. Goldin BR. Lactic acid bacteria: implication for health. In:Les Laits Fermentés. Actualités de la Recherche. Congrès International, Paris, 14-16 Decembre 1989. John Libbey Eurotext; 1990. pp. 95-104.
16. Henriksson R, Franzén L, Littbrand B. Prevention of irradiation-induced bowel discomfort by sucralfate: a double-blind, placebo-controlled study when treating localized pelvic cancer. Am J Med 1991; 91 (suppl 2A): 151S-157S.
17. Stryker JA, Chung CK, Layser JD. Colestipol hydrochloride prophylaxis of diarrhoea during pelvic radiotherapy. Int J Radiat Oncol Biol Phys 1983; 9: 185-190.
18. Chary S, Thomson DH. A clinical trial evaluating cholestyramine to prevent diarrhoea in patients maintained on low-fat diets during pelvic radiation therapy. Int J Radiat Oncol Biol Phys 1984; 10: 1885-1890.
19. Gilinsky NH, Burns DG, Barzebat GO, Levin W, Myers HS, Marks IN. The natural history of radiation-induced proctosigmoiditis: an analysis of 88 patients. Q J Med 1983; 52: 40-53.
20. Resbeut M, Marteau P, Cowen D, Richaud P, Bourdin S, Dubois JB. A randomised double blind placebo controlled multicenter study of mesalazine for the prevention of acute radiation enteritis. Radiother Oncol 1999; 44: 59-63.
21. Classen J, Belka C, Paulsen F, Budach W, Hoffmann W, Bamberg M. Radiation-induced gastrointestinal toxicity. Pathophysiology, approaches to treatment and prophylaxis. Strahlenther Onkol 1998; 174 (suppl 3): 82-84.
22. Ippoliti C. Antidiarrhoeal agents for the management of treatment-related diarrhoea in cancer patients. Am J Health Syst Pharm 1998; 55: 1573-1580.
23. Baillie-Johnson HR. Octreotide in the management of treatment-related diarrhoea. Anticancer Drugs 1996; 7 (suppl 1): 11-15.
24. Salminen E, Elomaa I, Minkkinen J, Vapaatalo H, Salminen S. Preservation of intestinal integrity during radiotherapy using live Lactobacillus acidophilus cultures. Clin Radiol 1988; 39: 435-437.